Pharma has been trying to drug RAS for forty years.
The first wins came from Mirati and Amgen with mutation-specific KRAS G12C inhibitors.
Useful, but limiting.
Most of these things target a SINGLE mutation – for example, in this case, it’s G12C.
That means the drugs only work in patients with this one mutation.
Patients with G12D, G13, Q61 and so on have to keep waiting in line.
The real prize has always been pan-KRAS – hit ANY KRAS mutation in ANY tumor type (but make sure you leave HRAS and NRAS alone so you don’t obliterate the patient’s healthy tissue).
Kestrel Therapeutics, a 28-person Allston biotech company tucked into Harvard’s Pagliuca Life Lab, thinks it’s there…and AbbVie wants the option to find out.
Why are we talking about this now?
Well, Kestreljust dosed the first patient in its Phase 1 FALCON trial of KST-6051, an oral pan-KRAS inhibitor, in advanced solid tumors.
Concurrently, the company entered a strategic warrant agreement with AbbVie giving the pharma giant an exclusive option to acquire the entire company, exercisable upon hitting predefined development milestones.
From what I can tell, no financial terms were disclosed.
That deal structure here is the real story. Forget the press release framing.
A warrant-to-acquire agreement is essentially AbbVie buying a call option on the whole company at a baked-in price, with the strike conditioned on clinical de-risking. Kestrel gets, presumably, an upfront payment plus development funding.
AbbVie gets first right of refusal, locks out competing bidders, and outsources the messy Phase 1 risk to Kestrel’s team and Kestrel’s existing investors.
The investors here include Pfizer Ventures, Section 32, Cormorant, Santé Ventures, and IQ Capital. Total raised so far is around $20.7 million. By Boston biotech standards, that’s a tight cap table for a company AbbVie wants exclusive rights to, which is part of why this kind of deal can be attractive to both sides.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
The mechanism?
KST-6051 binds KRAS in both the GTP-bound (active) and GDP-bound (inactive) states. Most KRAS inhibitors hit one or the other.
Targeting both should, in theory, prevent the protein from sneaking back into signaling competence after a dose.
The molecule is selective for KRAS over HRAS and NRAS, which is the toxicity story.
If KST-6051 holds up in the clinic, the indication footprint is enormous.
Pancreatic cancer, where over 90% of tumors carry KRAS mutations and survival has barely budged in decades.
Colorectal.
Non-small cell lung.
The sort of indications where any drug with even modest pan-KRAS activity could anchor a portfolio.
CEO Frank Haluska has been here before. He ran Anchiano Therapeutics, then Ariad Pharmaceuticals as CMO where he helped get multiple oncology drugs across the line. The board includes RAS biologists from Dana-Farber and Harvard Medical School.
This is not a middle school science-fair team.
The next 18-24 months will tell everyone whether AbbVie made a smart call buying optionality early, or whether KST-6051 joins the long graveyard of pan-KRAS attempts. Either way, the deal structure is one to study.
You’ll see more of these in 2026 and 2027.
The Biotech Voyager Podcast
Deep dives on the signals shaping early-stage biotech.
